Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

8.14.23

Engel Law PLLC is investigating whether fair value to Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE) shareholders will result from the proposed acquisition of Zynerba by Harmony Biosciences Holdings, Inc. (“Harmony”) (Nasdaq: HRMY) for (i) $1.1059 in cash, plus (ii) one non-tradable contingent value right per share (representing the right to receive potential additional payments of up to $140 million subject to the achievement of certain clinical, regulatory and sales milestones for Zygel — Zynerba’s lead new drug candidate) for each Zynerba share.

The Firm’s investigation concerns:

(i) whether the Company’s board of directors acted in the best interests of Company shareholders in agreeing to the proposed transaction;
(ii) whether the merger consideration adequately compensates the Company’s shareholders; and
(iii) whether all information regarding the sales process and valuation of the transaction will be fully and fairly disclosed.

Join this Action

Zynerba Pharmaceuticals, Inc.

Full Name or Entity

If Representing an Entity, Position at Entity

Address

Street Address Address Line 2 City State / Province / Region ZIP / Postal Code Country

Phone

Number of Shares Currently Owned

Date You Acquired Share(s)

Cost Per Share

Note

Consent(Required)

By clicking on the SUBMIT button below, I acknowledge that I have read the Retainer Agreement and agree to retain Engel Law PLLC to file an action or issue a shareholder demand against the Company in connection with this matter. Engel Law PLLC will prosecute this action on a contingent fee basis and will advance all costs and expenses.

Date of Signing(Required)

Zynerba Pharmaceuticals, Inc. (NASDAQ: ZYNE)

Join this Action

Zynerba Pharmaceuticals, Inc.

ENGEL LAW PLLC